The identification of a new key factor in VM development, β-catenin/TCF-4, would enable the introduction of a new treatment approach to reduce tumor growth due to the reduction of the ability to form VM in uveal melanoma cells that have previously been shown to have a mutation in GNAQ proteins (leading to constitutive FAK activation through YAP), which leaves them exposed to perform a targeted treatment in rare cancer as well as cutaneous melanoma. Here, PTK2 is linked to uveal melanoma.